Telcon RF Pharmaceutical Completes Capital Reduction Without Compensation...Trading Resumes
Telcon RF Pharmaceutical has completed its capital reduction without compensation.
On June 30, Telcon RF Pharmaceutical announced that it had completed the capital reduction procedure and would resume trading through a change of listing.
Telcon RF Pharmaceutical finished a 10-to-1 capital reduction without compensation on June 9 to offset its accumulated losses. Based on this, the company plans to strengthen the competitiveness of its pharmaceutical business division.
The company also intends to increase investment in production and logistics infrastructure. To enhance productivity, Telcon RF Pharmaceutical plans to build a palletizer and construct a new high rack warehouse with 2,000 cells to improve the efficiency of inbound and outbound operations for products from contract manufacturers.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative of Telcon RF Pharmaceutical stated, "We are reinforcing our business foundation so that we can stably generate more than 30 billion won in annual sales through expanded production capacity and facility investments in the pharmaceutical business division."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.